WO2022191550A1 - IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형 - Google Patents
IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형 Download PDFInfo
- Publication number
- WO2022191550A1 WO2022191550A1 PCT/KR2022/003207 KR2022003207W WO2022191550A1 WO 2022191550 A1 WO2022191550 A1 WO 2022191550A1 KR 2022003207 W KR2022003207 W KR 2022003207W WO 2022191550 A1 WO2022191550 A1 WO 2022191550A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- aqueous pharmaceutical
- pharmaceutical formulation
- concentration
- ige
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- 238000009472 formulation Methods 0.000 title claims abstract description 74
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 34
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 34
- 102000009109 Fc receptors Human genes 0.000 title claims abstract description 26
- 108010087819 Fc receptors Proteins 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 41
- 239000013636 protein dimer Substances 0.000 claims abstract description 29
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229930182817 methionine Natural products 0.000 claims abstract description 26
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 25
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 208000026935 allergic disease Diseases 0.000 claims abstract description 22
- 229940044519 poloxamer 188 Drugs 0.000 claims abstract description 19
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract description 19
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 7
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 7
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000000872 buffer Substances 0.000 claims description 28
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 claims description 22
- 101710128966 High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 239000000178 monomer Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims description 4
- 208000024376 chronic urticaria Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 3
- 206010016946 Food allergy Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 235000020932 food allergy Nutrition 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 208000030949 chronic idiopathic urticaria Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 24
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 5
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 48
- 230000035882 stress Effects 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 23
- 229960002885 histidine Drugs 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 230000000007 visual effect Effects 0.000 description 12
- 108010073816 IgE Receptors Proteins 0.000 description 11
- 102000009438 IgE Receptors Human genes 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 9
- 210000003630 histaminocyte Anatomy 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000009295 crossflow filtration Methods 0.000 description 7
- 239000012669 liquid formulation Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 238000011179 visual inspection Methods 0.000 description 7
- 238000012494 forced degradation Methods 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 210000003651 basophil Anatomy 0.000 description 5
- 239000012537 formulation buffer Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000004845 protein aggregation Effects 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229960000470 omalizumab Drugs 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 2
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 2
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 2
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 238000013400 design of experiment Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010889 donnan-equilibrium Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 1
- QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RZSLYUUFFVHFRQ-FXQIFTODSA-N Gln-Ala-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O RZSLYUUFFVHFRQ-FXQIFTODSA-N 0.000 description 1
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 1
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 229920002508 Poloxamer 181 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- JMZKMSTYXHFYAK-VEVYYDQMSA-N Thr-Arg-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O JMZKMSTYXHFYAK-VEVYYDQMSA-N 0.000 description 1
- KCRQEJSKXAIULJ-FJXKBIBVSA-N Thr-Gly-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O KCRQEJSKXAIULJ-FJXKBIBVSA-N 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000012059 flow imaging microscopy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940085692 poloxamer 181 Drugs 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000012602 primary packaging material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011856 silicon-based particle Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
Description
# | pH | 버퍼 성분 | 안정화제 | 설명 |
21 | 6.7 | 10 mM His/HCl | 250 mM 트레할로스 | 실제 pH 6.5를 갖는 액체 제형; 동결 건조된 제시를 위한 백업 |
22 | 6.7 | 10 mM His/HCl | 250 mM 만니톨 | pH 6.5를 갖는 액체 제형; 흔히 사용되는 부형제 |
23 | 6.7 | 10 mM His/HCl | 250 mM 프롤린 | pH 6.5를 갖는 액체 제형; 응집에 대한 경향이 더 낮을 수 있음 |
25 | 7.4 | 10 mM Tris/HCl | 250 mM 프롤린 | pH 7.4를 갖는 액체 제형; 완벽한 등장 상태, 그러나 화학적 안정성이 더 적을 수 있음 |
# | pH | 버퍼 성분 | 안정화제 |
1 | 6.7 | 10 mM His/HCl | 250 mM 트레할로스 |
2 | 6.7 | 10 mM His/HCl | 250 mM 만니톨 |
3 | 6.7 | 10 mM His/HCl | 250 mM 프롤린 |
4 | 7.4 | 10 mM Tris/HCl | 250 mM 프롤린 |
샘플 | ||||||
GI-301 농도 | 일차 포장 재료 | 방법 | #1 | #2 | #3 | #4 |
100 mg/mL | 2R 바이알 | 시각적 외관/침전 5℃에서 72시간 후 | √ | √ | √ | √ |
100 mg/mL | 2R 바이알 | 시각적 외관/침전 35℃에서 72시간 | √ | √ | √ | √ |
100 mg/mL | 1 mL 주사기 30G 캐뉼라 | 밀어내는 힘 | X | X | X | X |
시각적 외관/침전 | √ | √ | √ | √ | ||
100 mg/mL | 1 mL 주사기 27G 캐뉼라 | 밀어내는 힘 | √ | √ | √ | √ |
시각적 외관/침전 | √ | √ | √ | √ | ||
50 mg/mL | 1 mL 주사기 30G 캐뉼라 | 밀어내는 힘 | √ | √ | √ | √ |
시각적 외관/침전 | √ | √ | √ | √ | ||
pH-밀어냄의 영향 | √ | √ | √ | √ | ||
65 mg/mL (도넌 효과; 샘플 #2 - #4에 대한 보상) |
1 mL 주사기 27G 캐뉼라 | 밀어내는 힘 | √ | √ | √ | |
시각적 외관/침전 | √ | √ | √ | |||
pH-밀어냄의 영향 | √ | √ | √ | |||
SEC | √ | √ | √ | |||
ELISA | √ | √ | √ | |||
점도 | √ | √ | √ | |||
탁도 | √ | √ | √ | |||
삼투압 몰농도 | √ | √ | √ |
실험
방법 |
샘플 | ||||||||||||||||
#1 | #2 | #3 | #4 | ||||||||||||||
시각적 검사 |
5일, 35℃, 200 rpm |
14일, 35℃, 200 rpm | 빛 | 5일, 35℃, 200 rpm |
14일, 35℃, 200 rpm |
빛 | 5일, 35℃, 200 rpm |
14일, 35℃, 200 rpm |
빛 | 5일, 35℃, 200 rpm |
14일, 35℃, 200 rpm | 빛 | |||||
X | X | √ | √ | X | √ | √ | X | √ | √ | X | √ | ||||||
SE-HPLC | 14일, 35℃, 200 rpm |
빛 | 14일, 35℃, 200 rpm |
빛 | 14일, 35℃, 200 rpm |
빛 | 14일, 35℃, 200 rpm |
빛 | |||||||||
SE- HPLC |
메인 피크 (일반) |
√ | √ | X | X | ||||||||||||
응집물 | √ | √ | X | X | |||||||||||||
단편 | √ | X | X | √ |
캐뉼라 | Fmax[N] |
27G(0.4 mm OD) 12 mm | 10.6±0.5 |
30G(0.3 mm OD) 12 mm | 23.5±1.1 |
염기성 조성물 | 250 mM 프롤린, 히스티딘/HCl, pH 6.7 | |||||
첨가제 | #1(첨가제 없음) | #2 | #3 | #4 | #5 1) | #6 1) |
메티오닌 | 20 ㎎/mL | 20 ㎎/mL | 20 ㎎/mL | 20 ㎎/mL | ||
트윈 80 | 0.1 w/v% | 0.1 w/v% | ||||
플록사머 | 0.1 w/v% | |||||
트윈 20 | 0.1 w/v% |
샘플 | ||||||
#1 | #2 | #3 | #4 | #5 | #6 | |
빛 스트레스 7.5시간 750 W/m2 |
맑은 용액, 노란빛 |
맑은 용액, 노란빛 | 맑은 용액, 노란빛 |
맑은 용액, 노란빛 |
해당없음 | 해당없음 |
35℃, 200 rpm, 5일 |
가시적인 탁도, 옅은 노란빛 |
맑은 용액, 옅은 노란빛 |
가시적인 탁도, 옅은 노란빛 |
가시적인 탁도, 옅은 노란빛 |
맑은 용액, 옅은 노란빛 | 맑은 용액, 옅은 노란빛 |
35℃, 200 rpm, 14일 |
강한 탁도, 옅은 노란빛 |
맑은 용액, 옅은 노란빛 | 강한 탁도, 옅은 노란빛 |
강한 탁도, 옅은 노란빛 |
맑은 용액, 옅은 노란빛 | 약간의 탁도, 옅은 노란빛 |
샘플(n=2) | ||||||
#1 | #2 | #3 | #4 | #5 | #6 | |
c [mg/mL] | c [mg/mL] | c [mg/mL] | c [mg/mL] | c [mg/mL] | c [mg/mL] | |
35℃, 200 rpm, 5일 |
96.8±0.7 | 98.9±2.1 | 96.2±0.3 | 95.5±0.3 | 93.9±1.5 | 95.3±2.8 |
35℃, 200 rpm, 14일 |
102.1±1.6 | 94.3±1.7 | 96.5±2.5 | 94.5±1.5 | 95.6±1.0 | 96.0±2.5 |
빛 스트레스 7.5시간 750 W/m2 |
97.6±1.6 | 96.1±1.1 | 95.2±0.8 | 95.8±2.4 | - | - |
샘플(n=2) | ||||||
#1 | #2 | #3 | #4 | #5 | #6 | |
pH | pH | pH | pH | pH | pH | |
35℃, 200 rpm, 5일 |
6.82±0.01 | 6.74±0.00 | 6.74±0.00 | 6.72±0.00 | 해당없음 | 해당없음 |
35℃, 200 rpm, 14일 |
6.76±0.00 | 6.71±0.00 | 6.73±0.01 | 6.70±0.00 | 해당없음 | 해당없음 |
빛 스트레스 7.5시간 750 W/m2 |
6.72±0.01 | 6.72±0.00 | 6.71±0.01 | 6.70±0.01 | 해당없음 | 해당없음 |
샘플(n=2) | ||||||
스트레스 유형 |
#1 | #2 | #3 | #4 | #5 | #6 |
메인 피크 면적(main peak area)/퍼센트(%) | ||||||
35℃, 200 rpm, 5일 |
53.15±1.14 | 90.07±0.29 | 89.84±0.00 | 90.27±0.02 | 90.15±0.17 | 89.20±0.08 |
35℃, 200 rpm, 14일 |
36.83±0.08 | 88.07±0.05 | 87.52±0.04 | 87.89±0.05 | 87.78±0.03 | 86.19±0.01 |
빛 스트레스 | 92.97±0.07 | 94.08±0.45 | 93.12±0.43 | 93.74±0.52 | 해당없음 | 해당없음 |
응집 면적(aggregates area)/퍼센트(%) | ||||||
35℃, 200 rpm, 5일 |
5.78±0.23 | 8.20±0.08 | 8.72±0.04 | 8.24±0.06 | 8.26±0.11 | 9.23±0.05 |
35℃, 200 rpm, 14일 |
4.90±0.07 | 9.38±0.06 | 9.85±0.05 | 9.42±0.01 | 9.46±0.05 | 10.97±0.01 |
빛 스트레스 | 6.06±0.03 | 5.28±0.00 | 6.26±0.02 | 5.63±0.06 | 해당없음 | 해당없음 |
단편 면적(fragments area)/퍼센트(%) | ||||||
35℃, 200 rpm, 5일 |
41.07±1.37 | 1.73±0.21 | 1.44±0.03 | 1.50±0.04 | 1.59±0.05 | 1.58±0.13 |
35℃, 200 rpm, 14일 |
58.27±0.01 | 2.55±0.01 | 2.63±0.01 | 2.69±0.05 | 2.77±0.02 | 2.84±0.01 |
빛 스트레스 | 0.98±0.04 | 0.64±0.45 | 0.62±0.45 | 0.63±0.46 | 해당없음 | 해당없음 |
회수율(recovery)/퍼센트(%) | ||||||
35℃, 200 rpm, 14일 |
97.17±0.26 | 100.25±0.07 | 98.61±0.14 | 98.56±0.04 | 100.17±0.14 | 100.43±0.12 |
샘플(n=2) | ||||
#1 | #2 | #3 | #4 | |
35℃, 200 rpm, 5일 | 79.7%±3.8% | 112.7%±1.6% | 92.1%±5.2% | 94.3%±30.4 |
35℃, 200 rpm, 14일 | 104.9%±0.0% | 74.2%±6.5% | 80.4%±7.5% | 110.9%±12.6% |
빛 스트레스 | 110.2%±6.6% | 112.2%±5.1% | 110.1%±6.8% | 111.2%±3.3% |
샘플 (n=2) | ||||
#1 | #2 | #3 | #4 | |
NTU | NTU | NTU | NTU | |
35℃, 200 rpm, 5일 | 35.05±0.07 | 11.52±3.80 | 11.50±0.14 | 10.70±0.14 |
빛 스트레스 | 11.65±1.48 | 9.38±1.59 | 7.37±0.20 | 6.84±0.06 |
샘플(n=2) | ||||
#1 | #2 | #3 | #4 | |
mOSMOL/kg | mOSMOL/kg | mOSMOL/kg | mOSMOL/kg | |
35℃, 200 rpm, 5일 | 351±1 | 500±2 | 338±0 | 498±1 |
35℃, 200 rpm, 14일 | 363±1 | 488±3 | 333±1 | 492±0 |
빛 스트레스 | 338±2 | 496±1 | 338±1 | 495±0 |
샘플 | #1 | #2 | #3 | #4 | #5 | #6 |
35℃/200 rpm에서 14일 후 시각적 외관 | △ | ○ | × | × | ○ | △ |
35℃/200 rpm에서 14일 후 SEC 회수율 | × | ○ | △ | △ | ○ | ○ |
35℃/200 rpm에서 14일 후 SEC 메인 피크 | × | ○ | △ | ○ | ○ | × |
35℃/200 rpm에서 14일 후 DLS | △ | △ | × | × | △ | △ |
기본 성분 | 250 mM 프롤린, 히스티딘/HCl, pH 6.7 | |
첨가제 | #1 | #2 |
메티오닌 | 20 mg/mL | 20 mg/mL |
폴록사머 188 | - | 0.1 w/v% |
샘플 | ||
#1 | #2 | |
초기 상태 | 맑은 용액, 옅은 노란빛 | 맑은 용액, 옅은 노란빛 |
35℃, 200 rpm, 14일 | 맑은 용액, 옅은 노란빛 | 맑은 용액, 옅은 노란빛 |
27G (0.4 mm OD) 18 mm |
샘플 | |
#1 | #2 | |
Fmax[N] | Fmax[N] | |
n1 | 43.7 | 43.3 |
n2 | 42.6 | 41.0 |
샘플(n=2) | |||||
초기 상태 | 35℃, 200 rpm, 14일 후 | ||||
#1 | #2 | #1 시린지 1 |
#1 시린지 2 |
#2 시린지 1 |
#2 시린지 2 |
c[mg/mL] | c[mg/mL] | c[mg/mL] | c[mg/mL] | c[mg/mL] | c[mg/mL] |
98.9±2.9 | 99.6±1.6 | 100.2±1.2 | 101.3±0.8 | 98.2±1.0 | 98.9±0.7 |
샘플(n=2) | |||||
초기 상태 | 35℃, 200 rpm, 14일 후 | ||||
#1 | #2 | #1 시린지 1 |
#1 시린지 2 |
#2 시린지 1 |
#2 시린지 2 |
pH | pH | pH | pH | pH | pH |
6.74±0.00 | 6.77±0.01 | 6.75±0.01 | 6.73±0.03 | 6.75±0.00 | 6.75±0.00 |
샘플(n=2) | |||||
초기 상태(t0) | 35℃, 200 rpm, 14일 후 | ||||
#1 | #2 | #1 시린지 1 |
#1 시린지 2 |
#2 시린지 1 |
#2 시린지 2 |
메인 피크 면적(main peak area)/퍼센트(%) | |||||
93.87±0.14 | 93.73±0.03 | 83.83±0.04 | 83.74±0.16 | 84.44±0.41 | 84.10±0.11 |
응집 면적(aggregates area)/퍼센트(%) | |||||
4.36±0.04 | 4.49±0.01 | 9.60±0.04 | 9.61±0.08 | 9.40±0.16 | 9.48±0.05 |
단편 면적(fragments area)/퍼센트(%) | |||||
1.76±0.18 | 1.79±0.02 | 6.57±0.00 | 6.66±0.08 | 6.16±0.26 | 6.41±0.06 |
회수율(recovery)/퍼센트(%) | |||||
98.19±0.02 | 98.79±0.03 | 101.56±0.28 | 102.99±0.34 | 101.44±0.72 | 102.72±0.14 |
샘플(n=2) | |||||
초기 상태 | 35℃, 200 rpm, 14일 후 | ||||
#1 | #2 | #1 시린지 1 |
#1 시린지 2 |
#2 시린지 1 |
#2 시린지 2 |
mOSMOL/kg | mOSMOL/kg | mOSMOL/kg | mOSMOL/kg | mOSMOL/kg | mOSMOL/kg |
504±1 | 507±2 | 515±8 | 514±6 | 514±2 | 516±1 |
샘플 | #1 | #2 |
35℃/200 rpm에서 14일 후 시각적 외관 | ○ | ○ |
35℃/200 rpm에서 14일 후 SEC 회수율 | ○ | ○ |
35℃/200 rpm에서 14일 후 SEC 메인 피크 | ○ | ○ |
35℃/200 rpm에서 14일 후 DLS | △ | △ |
플로우 이미징 현미경(정성적) | ○ | ○ |
Claims (24)
- IgE Fc 수용체의 알파 서브유닛의 세포외 도메인(FcεRIα ECD)을 포함하는 융합단백질 이량체를 포함하며,pH 6.0 내지 7.0을 갖는 수성 약제학적 제형.
- 제1항에 있어서,상기 제형은 피하 주사용인, 수성 약제학적 제형.
- 제1항에 있어서,상기 융합단백질 이량체는 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 단량체 두 개를 포함하는 것인, 수성 약제학적 제형.
- 제3항에 있어서,상기 단량체는 변형된 Fc 영역을 포함하며,상기 변형된 Fc 영역과 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인은 힌지를 통해 결합된 것인, 수성 약제학적 제형.
- 제4항에 있어서,상기 변형된 Fc 영역은 서열번호 2로 이루어진 것인, 수성 약제학적 제형.
- 제4항에 있어서,상기 힌지는 면역글로불린 IgD에서 유래한 힌지 영역 또는 이의 변이체인 것인, 수성 약제학적 제형.
- 제1항에 있어서,상기 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인은 서열번호 1의 아미노산 서열 또는 이의 단편으로 이루어진 것인, 수성 약제학적 제형.
- 제1항에 있어서,상기 융합단백질 이량체의 농도가 50 ㎎/mL 내지 150 ㎎/mL인 것인, 수성 약제학적 제형.
- 제1항에 있어서,상기 제형은 버퍼 및 안정화제를 추가로 포함하는 것인, 수성 약제학적 제형.
- 제9항에 있어서,상기 버퍼는 히스티딘인 것인, 수성 약제학적 제형.
- 제10항에 있어서,상기 히스티딘의 농도가 10 mM 내지 100 mM인 것인, 수성 약제학적 제형.
- 제9항에 있어서,상기 안정화제는 프롤린인 것인, 수성 약제학적 제형.
- 제12항에 있어서,상기 프롤린의 농도가 200 mM 내지 300 mM인 것인, 수성 약제학적 제형.
- 제1항에 있어서,상기 제형은 항산화제를 추가로 포함하는 것인, 수성 약제학적 제형.
- 제14항에 있어서,상기 항산화제는 메티오닌인 것인, 수성 약제학적 제형.
- 제15항에 있어서,상기 메티오닌의 농도가 10 ㎎/mL 내지 30 ㎎/mL인 것인, 수성 약제학적 제형.
- 제1항에 있어서,상기 제형은 계면활성제를 추가로 포함하는 것인, 수성 약제학적 제형.
- 제17항에 있어서,상기 계면활성제는 폴록사머 188(poloxamer 188)인 것인, 수성 약제학적 제형.
- 제18항에 있어서,상기 폴록사머 188의 농도가 0.01 w/v% 내지 1 w/v%인 것인, 수성 약제학적 제형.
- i) 50 ㎎/mL 내지 150 ㎎/mL 농도의 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질 이량체;ii) 10 mM 내지 100 mM 농도의 히스티딘;iii) 200 mM 내지 300 mM 농도의 프롤린;iv) 10 ㎎/mL 내지 30 ㎎/mL 농도의 메티오닌; 및v) 0.01 w/v% 내지 1 w/v% 농도의 폴록사머 188을 포함하며,pH 6.0 내지 7.0을 갖는 수성 약제학적 제형.
- 제20항에 있어서,상기 제형은 바이알, 카트리지, 주사기 및 자동 주사기(autoinjector)로 이루어진 군으로부터 선택된 용기에 존재하는 것인, 수성 약제학적 제형.
- 제20항에 있어서,상기 제형은 피하 투여를 위한 것인, 수성 약제학적 제형.
- 제20항에 있어서,상기 제형은 알레르기 질환의 예방 또는 치료를 위한 것인, 수성 약제학적 제형.
- 제23항에 있어서,상기 알레르기 질환은 식품 알레르기, 아토피 피부염(atopic dermatitis), 천식(asthma), 알레르기성 비염(allergic rhinitis), 알레르기성 결막염(allergic conjunctivitis), 알레르기성 피부염(allergic dermatitis), 만성 특발성 두드러기(chronic idiopathic urticaria), 만성 자발성 두드러기(chronic spontaneous urticaria) 및 알레르기성 접촉성 피부염(allergic contact dermatitis)으로 구성된 군에서 선택된 하나인 것인, 수성 약제학적 제형.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PE2023002481A PE20240120A1 (es) | 2021-03-09 | 2022-03-07 | Formulacion de proteina de fusion que incluye el dominio extracelular de la subunidad alfa del receptor ige fc |
CA3211978A CA3211978A1 (en) | 2021-03-09 | 2022-03-07 | Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor |
EP22767446.2A EP4306103A1 (en) | 2021-03-09 | 2022-03-07 | Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor |
AU2022232566A AU2022232566A1 (en) | 2021-03-09 | 2022-03-07 | Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor |
US18/549,558 US20240148829A1 (en) | 2021-03-09 | 2022-03-07 | Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor |
JP2023555346A JP2024509937A (ja) | 2021-03-09 | 2022-03-07 | Ige fc受容体のアルファサブユニットの細胞外ドメインを含む融合タンパク質の製剤 |
CN202280016419.9A CN116963721A (zh) | 2021-03-09 | 2022-03-07 | 包含IgE Fc受体的α亚基的胞外结构域的融合蛋白的制剂 |
IL305512A IL305512A (en) | 2021-03-09 | 2022-03-09 | Formulation of a fusion protein comprising the extracellular domain of the alpha subunit of the IgE FC receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0030501 | 2021-03-09 | ||
KR20210030501 | 2021-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022191550A1 true WO2022191550A1 (ko) | 2022-09-15 |
Family
ID=83227989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/003207 WO2022191550A1 (ko) | 2021-03-09 | 2022-03-07 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20240148829A1 (ko) |
EP (1) | EP4306103A1 (ko) |
JP (1) | JP2024509937A (ko) |
KR (1) | KR20220126654A (ko) |
CN (1) | CN116963721A (ko) |
AU (1) | AU2022232566A1 (ko) |
CA (1) | CA3211978A1 (ko) |
CL (1) | CL2023001670A1 (ko) |
IL (1) | IL305512A (ko) |
PE (1) | PE20240120A1 (ko) |
TW (1) | TW202302138A (ko) |
WO (1) | WO2022191550A1 (ko) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7867491B2 (en) | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
KR20120103702A (ko) * | 2010-01-19 | 2012-09-19 | 에프. 호프만-라 로슈 아게 | 단백질용 약제학적 제형물 |
KR101783272B1 (ko) | 2008-09-17 | 2017-09-29 | 젠코어 인코포레이티드 | IgE-매개된 장애를 치료하기 위한 신규 조성물 및 방법 |
KR102038672B1 (ko) * | 2018-01-08 | 2019-10-30 | (주)지아이이노베이션 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
KR102038675B1 (ko) | 2018-01-08 | 2019-10-30 | (주)지아이이노베이션 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
WO2020097141A1 (en) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
US20200353049A1 (en) * | 2018-01-26 | 2020-11-12 | Genentech, Inc. | Compositions and methods of use |
-
2022
- 2022-03-07 CA CA3211978A patent/CA3211978A1/en active Pending
- 2022-03-07 KR KR1020220028919A patent/KR20220126654A/ko unknown
- 2022-03-07 WO PCT/KR2022/003207 patent/WO2022191550A1/ko active Application Filing
- 2022-03-07 PE PE2023002481A patent/PE20240120A1/es unknown
- 2022-03-07 US US18/549,558 patent/US20240148829A1/en active Pending
- 2022-03-07 CN CN202280016419.9A patent/CN116963721A/zh active Pending
- 2022-03-07 JP JP2023555346A patent/JP2024509937A/ja active Pending
- 2022-03-07 AU AU2022232566A patent/AU2022232566A1/en active Pending
- 2022-03-07 EP EP22767446.2A patent/EP4306103A1/en active Pending
- 2022-03-08 TW TW111108408A patent/TW202302138A/zh unknown
- 2022-03-09 IL IL305512A patent/IL305512A/en unknown
-
2023
- 2023-06-08 CL CL2023001670A patent/CL2023001670A1/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7867491B2 (en) | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
KR101783272B1 (ko) | 2008-09-17 | 2017-09-29 | 젠코어 인코포레이티드 | IgE-매개된 장애를 치료하기 위한 신규 조성물 및 방법 |
KR20120103702A (ko) * | 2010-01-19 | 2012-09-19 | 에프. 호프만-라 로슈 아게 | 단백질용 약제학적 제형물 |
KR102038672B1 (ko) * | 2018-01-08 | 2019-10-30 | (주)지아이이노베이션 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
KR102038675B1 (ko) | 2018-01-08 | 2019-10-30 | (주)지아이이노베이션 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
US20200353049A1 (en) * | 2018-01-26 | 2020-11-12 | Genentech, Inc. | Compositions and methods of use |
WO2020097141A1 (en) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
IL305512A (en) | 2023-10-01 |
AU2022232566A1 (en) | 2023-08-03 |
CN116963721A (zh) | 2023-10-27 |
PE20240120A1 (es) | 2024-01-22 |
TW202302138A (zh) | 2023-01-16 |
KR20220126654A (ko) | 2022-09-16 |
US20240148829A1 (en) | 2024-05-09 |
JP2024509937A (ja) | 2024-03-05 |
CL2023001670A1 (es) | 2023-11-24 |
CA3211978A1 (en) | 2022-09-15 |
EP4306103A1 (en) | 2024-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017078385A1 (en) | Formulation of modified interleukin-7 fusion protein | |
WO2014017845A2 (en) | A liquid formulation of long acting insulinotropic peptide conjugate | |
WO2015080513A1 (en) | A liquid formulation of a fusion protein comprising tnfr and fc region | |
AU2016346864B2 (en) | Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same | |
WO2010011096A2 (en) | A polypeptide complex comprising non-peptidyl polymer having three functional ends | |
WO2014017847A1 (en) | A liquid formulation of long-acting insulin conjugate | |
WO2018131893A1 (ko) | 안정한 액체 제제 | |
WO2015005747A1 (ko) | FcRn 결합력이 유지되는 면역글로불린 Fc 결합체 | |
WO2021096275A1 (ko) | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 | |
WO2022191550A1 (ko) | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형 | |
WO2022005113A1 (ko) | 항-FcRn 항체에 대한 제형 | |
WO2018169348A1 (ko) | 항-tnf 알파 항체의 액상 제제 | |
WO2020050626A1 (ko) | O-글리코실화 가능한 폴리펩타이드 영역을 포함하는 융합 폴리펩타이드 | |
WO2017116191A2 (ko) | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 | |
WO2020145789A1 (ko) | 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도 | |
WO2021096278A1 (ko) | 항체 의약품용 액상 조성물 | |
WO2021107603A2 (en) | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same | |
WO2020101452A1 (ko) | 단백질을 포함하는 안정한 액상 조성물 | |
WO2022045857A2 (ko) | 안정한 약제학적 제제 | |
WO2022010273A1 (ko) | 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도 | |
WO2018066891A2 (ko) | 인터페론 베타 변이체의 안정화 제제 | |
WO2023096475A1 (ko) | Hgh 융합단백질의 고농도 투여 제형 | |
WO2023132547A1 (ko) | 혈관신생 억제제가 결합된 항-c3b 항체 또는 항-c5 항체 및 이의 용도 | |
WO2022245179A1 (en) | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist | |
WO2022164061A1 (ko) | 단백질 제제의 안정성 향상을 위한 단백질 마이크로비드의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22767446 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023013087 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022232566 Country of ref document: AU Date of ref document: 20220307 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280016419.9 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 3211978 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 305512 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 002481-2023 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/010457 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18549558 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023555346 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 112023013087 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230629 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202306153Q Country of ref document: SG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023125493 Country of ref document: RU Ref document number: 2022767446 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022767446 Country of ref document: EP Effective date: 20231009 |